Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000947871-25-000490·Edgewise Therapeutics, Inc.
Schedule 13D ownership disclosure
Edgewise Therapeutics Inc
Common Stock · CUSIP: 28036F105
Event date: 2025-05-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 15,252,867.00 · Class: 14.5%
- ORBIMED CAPITAL GP VI LLCReported CIK 0001682115
Shares: 14,809,075.00 · Class: 14.1%
- OrbiMed Genesis GP LLCReported CIK 0001808744
Shares: 443,792.00 · Class: 0.4%
- ORBIMED CAPITAL LLCReported CIK 0001157524
Shares: 265,625.00 · Class: 0.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000490
- Form type
- SCHEDULE 13D/A
- Filer
- Edgewise Therapeutics, Inc.
- CIK
- CIK 1710072
- Filed
- May 12, 2025
- Reporting period
- May 09, 2025
- Description
- Schedule 13D beneficial ownership